IGF1R and Miyoshi myopathy: The OncoPredict algorithm showed that high-risk MM patients were more sensitive to 8 drugs, including Nutlin-3a (MDM2 inhibitor), SB216763 (GSK3 inhibitor), oxaliplatin (platinum anticancer drug), olaparib (PARP inhibitor), irinotecan (TopoI inhibitor), BMS-754807 (IGF-1R/IR inhibitor), AZD8055 (mTOR inhibitor), and camptothecin (TopoI inhibitor) (Figure 8).